Literature DB >> 20015576

Differential recognition of vascular and parenchymal beta amyloid deposition.

Kim S Rutgers1, Alexandra van Remoortere, Mark A van Buchem, C Theo Verrips, Steven M Greenberg, Brian J Bacskai, Matthew P Frosch, Sjoerd G van Duinen, Marion L Maat-Schieman, Silvère M van der Maarel.   

Abstract

By phage display, llama-derived heavy chain antibody fragments were selected from non-immune and immune libraries and tested for their affinity and specificity for beta amyloid by phage-ELISA, immunohistochemistry and surface plasmon resonance. We identified eight distinct heavy chain antibody fragments specific for beta amyloid. While three of them recognized vascular and parenchymal beta amyloid deposits, the remaining five heavy chain antibody fragments recognized vascular beta amyloid specifically, failing to bind to parenchymal beta amyloid. These heavy chain antibody fragments, selected from different libraries, demonstrated differential affinity for different epitopes when used for immunohistochemistry. These observations indicate that the llama heavy chain antibody fragments are the first immunologic probes with the ability to differentiate between parenchymal and vascular beta amyloid aggregates. This indicates that vascular and parenchymal beta amyloid deposits are heterogeneous in epitope presence/availability. The properties of these heavy chain antibody fragments make them potential candidates for use in in vivo differential diagnosis of Alzheimer disease and cerebral amyloid angiopathy. Continued use and characterization of these reagents will be necessary to fully understand the performance of these immunoreagents.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015576      PMCID: PMC2891162          DOI: 10.1016/j.neurobiolaging.2009.11.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium.

Authors:  Arumugam Muruganandam; Jamshid Tanha; Saran Narang; Danica Stanimirovic
Journal:  FASEB J       Date:  2001-12-28       Impact factor: 5.191

2.  Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA.

Authors:  Yvonne Kerwitz; Uwe Kühn; Hauke Lilie; Anne Knoth; Till Scheuermann; Henning Friedrich; Elisabeth Schwarz; Elmar Wahle
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

Review 3.  Prokaryotic expression of antibodies.

Authors:  Mehdi Arbabi-Ghahroudi; Jamshid Tanha; Roger MacKenzie
Journal:  Cancer Metastasis Rev       Date:  2005-12       Impact factor: 9.264

4.  Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles.

Authors:  R Natté; M L Maat-Schieman; J Haan; M Bornebroek; R A Roos; S G van Duinen
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

5.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

6.  Hereditary cerebral hemorrhage with amyloidosis-Dutch type: better correlation of cognitive deterioration with advancing age than with number of focal lesions or white matter hyperintensities.

Authors:  M Bornebroek; M A Van Buchem; J Haan; R Brand; J B Lanser; F T de Bruïne; R A Roos
Journal:  Alzheimer Dis Assoc Disord       Date:  1996       Impact factor: 2.703

7.  Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease.

Authors:  S G van Duinen; E M Castaño; F Prelli; G T Bots; W Luyendijk; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C).

Authors:  J Ghiso; O Jensson; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.

Authors:  P Seubert; T Oltersdorf; M G Lee; R Barbour; C Blomquist; D L Davis; K Bryant; L C Fritz; D Galasko; L J Thal
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

View more
  12 in total

1.  GREG cells, a dysferlin-deficient myogenic mouse cell line.

Authors:  Glen W Humphrey; Elena Mekhedov; Paul S Blank; Antoine de Morree; Gulcin Pekkurnaz; Kanneboyina Nagaraju; Joshua Zimmerberg
Journal:  Exp Cell Res       Date:  2011-10-12       Impact factor: 3.905

Review 2.  Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review.

Authors:  Yang Gao; Jianwei Zhu; Huili Lu
Journal:  Drug Deliv Transl Res       Date:  2020-11-05       Impact factor: 4.617

3.  Insights into Cerebral Amyloid Angiopathy Type 1 and Type 2 from Comparisons of the Fibrillar Assembly and Stability of the Aβ40-Iowa and Aβ40-Dutch Peptides.

Authors:  Jitika Rajpoot; Elliot J Crooks; Brandon A Irizarry; Ashley Amundson; William E Van Nostrand; Steven O Smith
Journal:  Biochemistry       Date:  2022-06-06       Impact factor: 3.321

4.  In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through?

Authors:  Benoît Delatour; Stéphane Epelbaum; Alexandra Petiet; Marc Dhenain
Journal:  Int J Alzheimers Dis       Date:  2010-09-30

5.  Copper stabilizes antiparallel β-sheet fibrils of the amyloid β40 (Aβ40)-Iowa variant.

Authors:  Elliot J Crooks; Brandon A Irizarry; Martine Ziliox; Toru Kawakami; Tiffany Victor; Feng Xu; Hironobu Hojo; Kelley Chiu; Carlos Simmerling; William E Van Nostrand; Steven O Smith; Lisa M Miller
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

6.  Development of a PET radioligand selective for cerebral amyloid angiopathy.

Authors:  Eric E Abrahamson; Jeffrey S Stehouwer; Alberto L Vazquez; Guo-Feng Huang; N Scott Mason; Brian J Lopresti; William E Klunk; Chester A Mathis; Milos D Ikonomovic
Journal:  Nucl Med Biol       Date:  2020-05-12       Impact factor: 2.408

7.  Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity.

Authors:  Antoine de Morrée; Paul J Hensbergen; Herman H H B M van Haagen; Irina Dragan; André M Deelder; Peter A C 't Hoen; Rune R Frants; Silvère M van der Maarel
Journal:  PLoS One       Date:  2010-11-05       Impact factor: 3.240

8.  Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.

Authors:  Eduard Gallardo; Noemi de Luna; Jordi Diaz-Manera; Ricardo Rojas-García; Lidia Gonzalez-Quereda; Bàrbara Flix; Antoine de Morrée; Silvère van der Maarel; Isabel Illa
Journal:  PLoS One       Date:  2011-12-16       Impact factor: 3.240

9.  In vivo detection of amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease.

Authors:  Rob J A Nabuurs; Kim S Rutgers; Mick M Welling; Athanasios Metaxas; Maaike E de Backer; Maarten Rotman; Brian J Bacskai; Mark A van Buchem; Silvère M van der Maarel; Louise van der Weerd
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

Review 10.  Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.

Authors:  Jan Klohs; Markus Rudin; Derya R Shimshek; Nicolau Beckmann
Journal:  Front Aging Neurosci       Date:  2014-03-13       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.